Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Edouard Januel (1) , Jérôme de Seze (2) , Patrick Vermersch (3) , Elisabeth Maillart (4) , Bertrand Bourre (5) , Julie Pique (6) , Xavier Moisset (7) , Caroline Bensa (8) , Adil Maarouf (9) , Jean Pelletier (10) , Sandra Vukusic (11) , Bertrand Audoin (9) , Céline Louapre (4, 1) , Kevin Bigaut (12) , Nathalie Derache (13) , Salimata Gassama (14) , Olivier Heinzlef (15) , Laurent Kremer , Philippe Kerschen (16) , Aude Maurousset , Vito a G Ricigliano

1 ICM - Institut du Cerveau = Paris Brain Institute
2 Service de Neurologie [Strasbourg]
3 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
4 CHU Pitié-Salpêtrière [AP-HP]
5 Service de neurologie [Rouen]
6 MIRCEM - Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle
7 Neuro-Dol - Neuro-Dol
8 Service de Neurologie [CHU Nice]
9 CRMBM - Centre de résonance magnétique biologique et médicale
10 CHU Marseille
11 Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL]
12 Centre d’Investigation Clinique Plurithématique (CIC - P) - CIC Strasbourg
13 Service de Neurologie [CHU Caen]
14 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
15 CHI Poissy-Saint-Germain
16 ENT - Excitabilité nerveuse et thérapeutique

Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients, and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.

Domaines: Maladies infectieuses

Edouard Januel, Jérôme de Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, et al.. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple Sclerosis Journal, 2021, pp.135245852110497. ⟨10.1177/13524585211049737⟩. ⟨hal-03526127⟩